TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7540461
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 micrograms/Kg B.W.) administered after chemotherapy cycles as needed
Study: 376883
Drug: Oral amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amphotericin B 50 mg four times a day
Study: 19038583
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium (100 mg)
Study: 17205440
Drug: Miltefosine, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine, 2.5 mg/kg/day for 28 days
Study: 17205440
Drug: Amphotericin B,
Normalized name: Amphotericin B, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphotericin B, 45 mg/kg over 90 days
Study: 3065355
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of mifepristone
Study: 3065355
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg of mifepristone
Study: 28877312
Drug: Topical fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluorouracil, 5%, cream applied twice daily for 2 to 4 weeks (28 to 56 doses)
Study: 28877312
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control cream applied twice daily for 2 to 4 weeks (28 to 56 doses)
Study: 28877312
Drug: Topical fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluorouracil, 5%, cream
Study: 23578589
Drug: Selling drugs
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selling drugs
Study: 12897732
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (estrogens, progestins, and their combination)
Study: 11350672
Drug: Damp gauze
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Damp gauze (Group G)
Study: 1305312
Drug: Etodolac 300
Normalized name: etodolac 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 300 mg b.i.d.
Study: 1305312
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg/day plus placebo
Study: 3906106
Drug: Progesterone treatment
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone treatment (100 mg twice daily delivered in vaginal pessaries)
Study: 26855018
Drug: Liraglutide (glucagon‐like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (glucagon‐like peptide‐1 receptor agonist)
Study: 24356862
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring-based dose adaptation strategy
Study: 21851293
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy (modified CIMT) at home (n=7)
Study: 21851293
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy (modified CIMT) at clinic (n=7)
Study: 24189085
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg liraglutide
Study: 20417856
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg liraglutide vs Sitagliptin
Study: 20417856
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg liraglutide vs Sitagliptin
Study: 20417856
Drug: Liraglutide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (both doses)
Study: 15694949
Drug: Fluvastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin, 40 mg daily
Study: 12672708
Drug: Whole tablet
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole tablet dietary supplement
Study: 12672708
Drug: Crushed tablet
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablet dietary supplement
Study: 10881002
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) 25 mg/m(2), i.v., weekly, x4 (cumulative dose 100 mg/m(2))
Study: 1571905
Drug: Accelerated superfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated superfractionated radiation therapy using a concomitant boost twice‐a‐day schedule (BID); 180 cGy/fraction with a boost of 160 cGy/fraction BID, 3 days per week.
Study: 1571905
Drug: Conventional once‐a‐day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional once‐a‐day (QD) fractionation to doses in excess of 6600 cGy.
Study: 29282469
Drug: Esketamine 28
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine 28 mg
Study: 29282469
Drug: Esketamine 56
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 56 mg
Study: 30401610
Drug: 24,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24,000 IU vitamin D3 plus 300 μg calcifediol/mo
Study: 18042032
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 2% lidocaine gel intrarectally 10 minutes before biopsy
Study: 18042032
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of intrarectal 40% DMSO with lidocaine equal to that in the lidocaine gel 10 minutes before procedure
Study: 11213851
Drug: Lamotrigine chewable
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine chewable dispersible tablets administered rectally
Study: 11213851
Drug: Lamotrigine chewable
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine chewable dispersible tablets administered orally
Study: 8101813
Drug: Buserelin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (20 micrograms, nasal spray, daily for 28 days)
Study: 27501953
Drug: Flapless (FLS)
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flapless (FLS) immediate implant placement
Study: 27501953
Drug: Flap-involving (F)
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flap-involving (F) immediate implant placement
Study: 23271103
Drug: Insulin levels
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin levels greater than 15 µU/mL
Study: 23271103
Drug: Insulin levels
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin levels of 5 µU/mL to 15 µU/mL
Study: 16183735
Drug: Self-administered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered treatment (control group)
Study: 12932604
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day for 8 weeks
Study: 8667129
Drug: Supportive periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive periodontal treatment (SPT)
Study: 1297876
Drug: Cardil, 240‐360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardil, 240‐360 mg/day
Study: 1297876
Drug: Cordafen, 30‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordafen, 30‐60 mg/day
Study: 28039317
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon β‐1a (sc IFN β‐1a) three times weekly (tiw)
Study: 28039317
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon β‐1a (sc IFN β‐1a) once weekly (qw)
Study: 23446085
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (DT)
Study: 28039317
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon β‐1a (sc IFN β‐1a) tiw
Study: 28039317
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon β‐1a (sc IFN β‐1a) qw and tiw
Study: 25559065
Drug: BCQB 180μg
Normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCQB 180μg co-administered with paroxetine 20mg
Study: 23817631
Drug: Biological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological treatment with infliximab
Study: 23817631
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with sulfasalazine plus hydroxychloroquine
Study: 21062337
Drug: Scalloped implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalloped implant group (20 patients)
Study: 21062337
Drug: Flat implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat implant group (20 patients)
Study: 18821458
Drug: Behavioral Therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Therapy for Depression in Drug Dependence (BTDD)
Study: 16505753
Drug: Patient-Controlled Sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Sedation (PCS) with propofol (20-mg boluses)
Study: 16505753
Drug: Standard sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sedation (control group) with continuous infusion of propofol
Study: 7494655
Drug: Sucrose 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose 50% (2 mL)
Study: 7494655
Drug: Placebo (distilled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (distilled water, 2 mL)
Study: 30447348
Drug: Povidone-iodine solution
Normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution 10% for about 1 min
Study: 22314101
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng extract (9 capsules per day for 3 months)
Study: 22314101
Drug: Placebo (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (9 capsules per day for 3 months)
Study: 14698828
Drug: Trichloroacetic acid
Normalized name: Trichloroacetic Acid
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trichloroacetic acid (TCA) after administration of danazol
Study: 14698828
Drug: Trichloroacetic acid
Normalized name: Trichloroacetic Acid
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trichloroacetic acid (TCA) after administration of goserelin acetate
Study: 11556125
Drug: Enteric-coated pellets
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated pellets containing 75 mg diclofenac sodium (A)
Study: 11556125
Drug: Enteric-coated tablet
Normalized name: Walgreens Low Dose Aspirin 81mg Enteric-Coated Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated tablet with 50 mg diclofenac sodium (B)
Study: 11556125
Drug: Capsule containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing 140 mg diclofenac resinate (C)
Study: 11556125
Drug: Dispersible tablet
Normalized name: Aspirin 75 mg orodispersible tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablet containing 46.5 mg diclofenac acid (D)
Study: 7798613
Drug: Topical retinaldehyde
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinaldehyde 1%
Study: 7798613
Drug: Topical retinaldehyde
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinaldehyde 0.5%
Study: 7798613
Drug: Topical retinaldehyde
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinaldehyde 0.1%
Study: 10473959
Drug: Topical retinaldehyde
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinaldehyde 0.05%
Study: 7798613
Drug: Topical retinaldehyde
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinaldehyde (0.5%, 0.1%, 0.05%)
Study: 25622123
Drug: 380 mg
Normalized name: aspirin 380 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 380 mg naltrexone injection + weekly psychotherapy for 4 weeks
Study: 10484048
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only diet therapy)
Study: 8564488
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular mass heparin (LMMH) (70 anti‐Xa units/kg b.w.)
Study: 8564488
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular mass heparin (LMMH)
Study: 1769130
Drug: Pyridostigmine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (2 mg/kg p.o.)
Study: 30323055
Drug: Inhaled cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cannabis (100 mg dose)
Study: 23748474
Drug: Phenobarbitone (PB)
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (PB) 10 mg/kg/day on day 1 followed by 5 mg/kg/day on days 2-5
Study: 23748474
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (control)
Study: 20946161
Drug: Sildenafil (flexible-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (flexible-dose of 25, 50, or 100 mg)
Study: 18783652
Drug: Intratumoral radiotracer
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral radiotracer administration (n=35)
Study: 18783652
Drug: Peritumoral radiotracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritumoral radiotracer administration (n=45)
Study: 18783652
Drug: Intratumoral radiotracer
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral radiotracer administration
Study: 18783652
Drug: Peritumoral radiotracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritumoral radiotracer administration
Study: 9372661
Drug: Lung-protective approach
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung-protective approach (LPA) with permissive hypercapnia (PHY), VT < 6 ml/kg, distending pressures above PEEP < 20 cm H2O, and PEEP 2 cm H2O above the lower inflection point on the static inspiratory P-V curve (P(FLEX))
Study: 17353866
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone treatment
Study: 3894871
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of glucose (G)
Study: 3894871
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of fructose (F)
Study: 28475473
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplement (50,000 units, one every fortnight for 8 weeks)
Study: 26306589
Drug: Urinary Magnesium
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary Magnesium to Creatinine ratio (Mg/Cr)
Study: 1986602
Drug: Fluoxetine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine administration
Study: 12841498
Drug: Mycobacterium w
Normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium w (immuvac) as adjuvant therapy
Study: 12841498
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (cisplatin and etoposide) and radiotherapy (control group)
Study: 8862741
Drug: Fluid and
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid and salt supplementation (0.1 g sodium chloride/kg body weight and 30 mL water/kg body weight) during hypokinesia
Study: 1284152
Drug: Gallopamil (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (0.4 mg)
Study: 3890508
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin followed by oral warfarin
Study: 9784040
Drug: Terbinafine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (125 or 250 mg/day) for 1 week
Study: 9784040
Drug: Terbinafine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (125 or 250 mg/day) for 2 weeks
Study: 9784040
Drug: Terbinafine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (125 or 250 mg/day) for 4 weeks
Study: 8112206
Drug: Fibrin injection
Normalized name: thrombin
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin injection (with adrenalin: n = 11; without adrenalin: n = 29)
Study: 8112206
Drug: Polidocanol injection
Normalized name: polidocanol Injection
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol injection (with adrenalin: n = 17; without adrenalin: n = 8)
Study: 8112206
Drug: Adrenalin injection
Normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenalin injection alone (n = 15)
Study: 2481163
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Nifedipine and Metoprolol
Study: 2468838
Drug: Nifedipine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (in patients already on beta-blocker)
Study: 11286323
Drug: tolterodine L‐tartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine L‐tartrate ER 8 mg (2 x 4 mg capsules) with a standardised high‐fat breakfast
Study: 11286323
Drug: tolterodine L‐tartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine L‐tartrate ER 8 mg (2 x 4 mg capsules) on an empty stomach
Study: 11286323
Drug: tolterodine L‐tartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine L‐tartrate IR 4 mg (2 x 2 mg tablets) administered in the fasting state
Study: 30099530
Drug: Statin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin with a run-in period (test dose)
Study: 30099530
Drug: Statin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin without a run-in period (no test dose)
Study: 25895202
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of vitamin D + 600 mg of calcium lactate (VD-Ca group)
Study: 25895202
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients with 400 IU of vitamin D + 600 mg of calcium lactate (MMN-VD-Ca group)
Study: 11136298
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg once daily for 5 days
Study: 15297200
Drug: Topotecan (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.0 mg/m(2)/day on days 1 to 3) and Carboplatin (AUC 4 on day 1) followed by Paclitaxel (175 mg/m(2) via 3‐h IV infusion on day 1) and Carboplatin (AUC 5 on day 1)
Study: 24619991
Drug: Prenatal Qi
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal Qi exercise (90 minutes, twice a week for 12 weeks)
Study: 23708168
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin level ≥10 g/dL)
Study: 23708168
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin <8 g/dL or symptoms from anemia)
Study: 21387981
Drug: Oral irrigator
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irrigator with prototype jet tip
Study: 21387981
Drug: Oral irrigator
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irrigator with standard jet tip
Study: 15570285
Drug: Hydroxyurea (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (30 mg/kg/day)
Study: 15570285
Drug: Busulphan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulphan (0.1 mg/kg/day)
Study: 11122135
Drug: 10 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg/kg G‐CSF once daily (n = 25)
Study: 11122135
Drug: 5 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg/kg G‐CSF twice daily (n = 25)
Study: 27212247
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment (15‐20mg/kg/day) for 24 weeks
Study: 24697979
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of naproxen 500 mg and apixaban 10 mg
Study: 19045972
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control group (no treatment during intervention period)
Study: 10630793
Drug: AIK-C vaccine
Normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIK-C vaccine
Study: 10630793
Drug: Schwarz vaccine
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz vaccine
Study: 7717832
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose heparin
Study: 22295884
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (75 mg)
Study: 2044396
Drug: Pethidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (75 mg)
Study: 7314025
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol and aminophylline